There's little harm in occasionally holding it in longer, but there are long-term risks if you regularly push your bladder's ...

Experts have explained the red flags and common signs of bladder cancer as 10,000 people are diagnosed in the UK every year ...

CG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, ...

The Food and Drug Administration on Monday approved Culver City-based ImmunityBio’s treatment for bladder cancer.

L.A. Times owner Patrick Soon-Shiong joins ‘Cavuto: Coast to Coast’ to discuss the backlash his company has faced for ...

New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1 TAR-200 provides durable CRs in patients with Bacillus ...

May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk ...

Radtke, MD, discusses the latest breakthroughs in bladder cancer treatment with erdafitinib, an FGFR1-4 inhibitor.

CG Oncology (NASDAQ:CGON), which went public in late January, reported data for its drug cretostimogene as a monotherapy in the treatment of a certain type of bladder cancer. The biotech company said ...

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to ...

The U.S. health regulator on Monday approved ImmunityBio's combination therapy to treat a type of bladder cancer, marking an ...

Newly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year, while offering a more comprehensive look at how its drug stacks up to rival therapies.